RecruitingPhase 2NCT05003986
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Studying Nephrotic syndrome without extrarenal manifestations
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Travere Therapeutics, Inc.
- Principal Investigator
- Radko Komers, MD, PhDTravere Therapeutics, Inc.
- Intervention
- Sparsentan(drug)
- Enrollment
- 67 enrolled
- Eligibility
- 1-17 years · All sexes
- Timeline
- 2021 – 2027
Study locations (30)
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- Nemours Children's Hospital, Wilmington, Delaware, United States
- University of Miami, Leonard M. Miller School of Medicine, Miami, Florida, United States
- Nicklaus Children's Hospital, Miami, Florida, United States
- University of Iowa, Stead Family Children's Hospital, Iowa City, Iowa, United States
- Floating Hospital for Children at Tufts Medical Center, Boston, Massachusetts, United States
- C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States
- University of Minnesota, Masonic Children's Hospital, Minneapolis, Minnesota, United States
- Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Jersey Shore University Medical Center, Neptune City, New Jersey, United States
- Cohen Children's Medical Center, New Hyde Park, New York, United States
- Fink Children's Ambulatory Care Center, New York, New York, United States
- University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
- Atrium Health Levine Children's Hospital, Charlotte, North Carolina, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05003986 on ClinicalTrials.govOther trials for Nephrotic syndrome without extrarenal manifestations
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07267026A Study to Evaluate the Safety, Tolerability and PK of SK-09Consun Pharmaceutical Group
- RECRUITINGPHASE4NCT07219121Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental GlomerulosclerosisTravere Therapeutics, Inc.
- RECRUITINGNANCT06867471Effects of Exogenous Ketosis on Proteinuria and Renal FunctionGødstrup Hospital
- RECRUITINGPHASE3NCT05716880Ketoanalogues for Muscle Mass Loss in Nephrotic SyndromeMilitary Institute od Medicine National Research Institute
- RECRUITINGNCT01209000Nephrotic Syndrome Study NetworkUniversity of Michigan
- RECRUITINGNCT01094327Proteinuria in Pre and Post TransplantUniversity of Miami
See all trials for Nephrotic syndrome without extrarenal manifestations →